Kite and Refuge Biotechnologies to work together to research blood cancer
The licence agreement bolsters Kite’s expertise in synthetic biology for oncology
Read Moreby Fleur Jeffries | Oct 21, 2022 | News | 0
The licence agreement bolsters Kite’s expertise in synthetic biology for oncology
Read Moreby Lucy Parsons | Jun 23, 2021 | News | 0
Partnership will advance the early clinical development of CAR-T cell engager candidate ALETA-001
Read Moreby Lucy Parsons | May 4, 2021 | News | 0
Targeting a specific mutation in the CUX1 gene may offer a ‘new therapy avenue’ for AML patients
Read Moreby Lucy Parsons | Dec 9, 2020 | News | 0
‘Encouraging’ data for investigational candidates across a range of blood cancers
Read Moreby Selina McKee | Jun 16, 2020 | News | 0
The drug is already on the market to treat chronic lymphocytic leukaemia (CLL)
Read Moreby Anna Smith | Sep 5, 2019 | News | 0
The company has released a short documentary and five mini-films, outlining the symptoms that led patients to their diagnosis.
Read Moreby Selina McKee | May 8, 2018 | News | 0
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
Read Moreby Selina McKee | Jan 17, 2018 | News | 0
The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479